Literature DB >> 18479637

Natural history of hearing loss in children with enlarged vestibular aqueduct syndrome.

Tyler Mori1, Brian D Westerberg, Shahnaz Atashband, Frederick K Kozak.   

Abstract

OBJECTIVE: To determine the natural history of hearing loss in children with enlarged vestibular aqueduct (EVA) syndrome.
DESIGN: (1) Retrospective cohort study and (2) systematic literature review.
SETTING: Tertiary pediatric centre.
METHODS: (1) Charts of children assessed by one physician between 1993 and 2000 were reviewed. (2) Source articles were identified by a search of Medline, Embase, and the Cochrane Library of the English-language literature through January 2006, with manual review of references. The search was limited to English, human, and age less than 18 years. MAIN OUTCOME MEASURES: Pure-tone average. Hearing was classified as stable, progressive and fluctuating.
RESULTS: (1) Twenty-one children (39 ears) with EVA were identified. Eighty-two percent of ears had stable hearing, and 18% of ears demonstrated progressive hearing loss. (2) Seven source articles were identified and combined with the present data for a total of 310 ears with a mean follow-up of 4 years. Bilateral EVA was found to be six times more common than unilateral EVA, and there was an equal male to female ratio. Stable hearing was found in 67% of ears and progressive hearing loss in 33% of ears. Subgroup analysis demonstrated hearing fluctuations in 50% of progressive hearing loss ears and 34% of stable ears.
CONCLUSIONS: Stable hearing is observed in 67% of ears with EVA of which 34% will demonstrate fluctuations in hearing. Progression of hearing loss is seen in 33% of ears of which half will demonstrate fluctuations.

Entities:  

Mesh:

Year:  2008        PMID: 18479637

Source DB:  PubMed          Journal:  J Otolaryngol Head Neck Surg        ISSN: 1916-0208


  7 in total

1.  Outcomes of Cochlear Implantation in Patients with Pendred syndrome: A Systematic Review and Narrative Synthesis.

Authors:  Kirsty Biggs; Amy Lovett; Chris Metcalfe; Jameel Muzaffar; Peter Monksfield; Manohar Bance
Journal:  J Int Adv Otol       Date:  2020-12       Impact factor: 1.017

2.  SLC26A4 mutation testing for hearing loss associated with enlargement of the vestibular aqueduct.

Authors:  Taku Ito; Julie Muskett; Parna Chattaraj; Byung Yoon Choi; Kyu Yup Lee; Christopher K Zalewski; Kelly A King; Xiangming Li; Philine Wangemann; Thomas Shawker; Carmen C Brewer; Seth L Alper; Andrew J Griffith
Journal:  World J Otorhinolaryngol       Date:  2013-05-28

3.  Newborn genetic screening for hearing impairment: a preliminary study at a tertiary center.

Authors:  Chen-Chi Wu; Chia-Cheng Hung; Shin-Yu Lin; Wu-Shiun Hsieh; Po-Nien Tsao; Chien-Nan Lee; Yi-Ning Su; Chuan-Jen Hsu
Journal:  PLoS One       Date:  2011-07-19       Impact factor: 3.240

4.  Outcomes of Gene Panel Testing for Sensorineural Hearing Loss in a Diverse Patient Cohort.

Authors:  Elizabeth N Liao; Emily Taketa; Noura I Mohamad; Dylan K Chan
Journal:  JAMA Netw Open       Date:  2022-09-01

5.  Differences in the pathogenicity of the p.H723R mutation of the common deafness-associated SLC26A4 gene in humans and mice.

Authors:  Ying-Chang Lu; Chen-Chi Wu; Ting-Hua Yang; Yin-Hung Lin; I-Shing Yu; Shu-Wha Lin; Qing Chang; Xi Lin; Jau-Min Wong; Chuan-Jen Hsu
Journal:  PLoS One       Date:  2013-06-03       Impact factor: 3.240

6.  Toward the Pathogenicity of the SLC26A4 p.C565Y Variant Using a Genetically Driven Mouse Model.

Authors:  Chin-Ju Hu; Ying-Chang Lu; Ting-Hua Yang; Yen-Hui Chan; Cheng-Yu Tsai; I-Shing Yu; Shu-Wha Lin; Tien-Chen Liu; Yen-Fu Cheng; Chen-Chi Wu; Chuan-Jen Hsu
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923

7.  Insights into phenotypic differences between humans and mice with p.T721M and other C-terminal variants of the SLC26A4 gene.

Authors:  Chin-Ju Hu; Ying-Chang Lu; Cheng-Yu Tsai; Yen-Hui Chan; Pei-Hsuan Lin; Yi-Shan Lee; I-Shing Yu; Shu-Wha Lin; Tien-Chen Liu; Chuan-Jen Hsu; Ting-Hua Yang; Yen-Fu Cheng; Chen-Chi Wu
Journal:  Sci Rep       Date:  2021-10-25       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.